Prurigo Nodularis Clinical Studies

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

Enrollment status: Open

Prurigo nodularis (PN), is a chronic itchy skin condition characterized by multiple raised bumps in the skin called “nodules". There is no one specific cause of purigo nodularis. We are studying an investigational drug called nemolizumab as a possible treatment. Nemolizumab is a type of biological drug called a monoclonal antibody. It blocks the binding of interleukin-31 (an immune system signaling molecule produced by the body) to its receptor. By blocking the binding, nemolizumab is expected to break the itch-scratch cycle and allow the skin to heal. The main purpose of this research study is to learn how effective (how well it works) and safe the study drug is which will be determined by how our subjects respond to treatment.

Study coordinator: Nicole Nechiporchik, (734) 232-0562 or dermtrials@med.umich.edu
Please reference Derm #: 740

Single cell Transcriptomic Resolution of Atopic Dermatitis and Prurigo Nodularis

The purpose of this study is to collect skin samples from people with eczema/dermatitis, or prurigo nodularis, and from those who don’t, also known as healthy controls. The samples, along with the clinical data, will be used by Dr. Gudjonsson for exploratory research, that may help him improve the ability to predict, detect, and monitor diseases and their progression. As well, exploratory research may lead to the development of new therapies, research methods or technologies.

Study coordinator: Lina Nahlawi, (734) 936-4075 or lnahlawi@med.umich.edu
Please reference Derm #: 749